+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Car T Therapies"

From
CAR-T Therapy Pipeline Analysis Global Market Report 2023 - Product Thumbnail Image

CAR-T Therapy Pipeline Analysis Global Market Report 2023

  • Report
  • February 2023
  • 175 Pages
  • Global
From
From
CAR T-cell Therapy - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-cell Therapy - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
CAR-T - Epidemiology Forecast - 2032 - Product Thumbnail Image

CAR-T - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
CD19/CD20 Bi-specific CAR-T - Epidemiology Forecast - 2032 - Product Thumbnail Image

CD19/CD20 Bi-specific CAR-T - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024 - Product Thumbnail Image

CD19/CD20 Bi-Specific CAR-T - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024 - Product Thumbnail Image

CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Neuroblastoma - Pipeline Insight, 2024 - Product Thumbnail Image

Neuroblastoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Castrate Resistant Prostrate Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
From
Metastatic Liver Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Metastatic Liver Cancer - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Osteosarcoma - Pipeline Insight, 2024 - Product Thumbnail Image

Osteosarcoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Anti-CD22 Therapies - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD22 Therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Anti-CD30 Therapies - Pipeline Insight, 2024 - Product Thumbnail Image

Anti-CD30 Therapies - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
CAR T - Cell Therapy - Competitive landscape, 2023 - Product Thumbnail Image

CAR T - Cell Therapy - Competitive landscape, 2023

  • Report
  • April 2023
  • 500 Pages
  • Global
From
Loading Indicator

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer. Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer. Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more